Ongoing Clinical Trials for Crohn’s Disease

Crohn’s disease is a chronic inflammatory condition affecting the digestive tract. Currently, there are 69 clinical trials investigating various treatments for this condition, including biological therapies, stem cell treatments, and new medications. These studies are taking place across multiple European countries and aim to improve treatment options for patients with moderate to severe Crohn’s disease.

Clinical trial locations

• Austria
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells for Treating Inflammatory Bowel Strictures in Crohn’s Disease Patients
  • See more trials
• Belgium
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Managing Moderate Postoperative Recurrence in Crohn’s Disease with Infliximab for Patients After Ileocolonic Surgery
  • Study on Preventing Crohn’s Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk
  • Study on Transmural Healing in Patients with Moderate to Severe Crohn’s Disease Using Upadacitinib and Drug Combination
  • Study on Upadacitinib for Children with Moderate to Severe Crohn’s Disease
  • See more trials
• Bulgaria
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Safety and Effects of Tulisokibart for Patients with Moderate to Severe Crohn’s Disease
• Croatia
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn’s Disease
  • Study on Guselkumab for Patients with Moderate to Severe Crohn’s Disease
• Czechia
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms
  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • See more trials
• Denmark
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on Vedolizumab and Ustekinumab for Patients with Crohn’s Disease and Ulcerative Colitis
  • Long-term study of upadacitinib tablets for adults with Crohn’s disease
  • Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells for Treating Inflammatory Bowel Strictures in Crohn’s Disease Patients
• Estonia
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
• Finland
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on the Safety and Effectiveness of AZD7798 for Adults with Ileal Crohn’s Disease and an Ileostomy
  • Study on Fecal Microbiota Transplantation with Infliximab and Vedolizumab for Patients with Ulcerative Colitis
• France
  • Study Comparing Vedolizumab and Adalimumab for Crohn’s Disease Patients Who No Longer Respond to Adalimumab
  • Study of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells and Microfat for Patients with Refractory Perianal Crohn’s Disease Fistulas
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on EXL01 for Preventing Crohn’s Disease Recurrence After Surgery in Patients
  • Study on Fecal Microbiota Transplantation for Crohn’s Disease Patients in Remission After Stopping Anti-TNF Therapy
  • Study on Using Fluorescein Sodium to Identify Inflammation in Crohn’s Disease Patients During Ileal Surgery
  • See more trials
• Germany
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on INTESTIFIX for Maintaining Remission in Children and Adults with Crohn’s Disease After Exclusive Enteral Nutrition Treatment
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms
  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • See more trials
• Greece
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn’s Disease
• Hungary
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • See more trials
• Ireland
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn’s Disease
• Italy
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on Managing Moderate Postoperative Recurrence in Crohn’s Disease with Infliximab for Patients After Ileocolonic Surgery
  • Study on Preventing Crohn’s Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • See more trials
• Latvia
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease
• Lithuania
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease
• Netherlands
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Using Ultrasound with Perflubutane and Laxative for Detecting Crohn’s Disease in Patients
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • See more trials
• Norway
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Using Ultrasound with Perflubutane and Laxative for Detecting Crohn’s Disease in Patients
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Long-term Safety of Guselkumab for Children with Crohn’s Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
• Poland
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Long-term Safety of Vedolizumab and Prednisone in Children with Ulcerative Colitis or Crohn’s Disease
  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms
  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • See more trials
• Portugal
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease
  • See more trials
• Romania
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn’s Disease
• Slovakia
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • See more trials
• Slovenia
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
• Spain
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn’s Disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of Mirikizumab for Children with Moderate to Severe Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
  • Study on Managing Heart Failure and Kidney Disease in Elderly Patients with High Potassium Risk Using Sodium Zirconium Cyclosilicate
  • Study on Managing Moderate Postoperative Recurrence in Crohn’s Disease with Infliximab for Patients After Ileocolonic Surgery
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments
  • See more trials
• Sweden
  • Study of AZD7798 compared to placebo in patients with moderate to severe Crohn’s disease
  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease
  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms
  • Study on the Safety and Effectiveness of AZD7798 for Adults with Ileal Crohn’s Disease and an Ileostomy
  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease
  • Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn’s Disease
  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease

Summary

There are currently 69 clinical trials investigating treatments for Crohn’s disease across Europe. These studies are examining a wide range of therapeutic approaches, from biological medications to innovative cell-based therapies.

The geographic distribution shows that trials are concentrated primarily in Western and Central European countries. Belgium, Germany, France, and the Netherlands are hosting the largest number of studies. Poland and Italy also have significant trial activity, while countries such as Spain, Hungary, and the Czech Republic participate in multiple studies. This distribution reflects both the research infrastructure available in these countries and the prevalence of Crohn’s disease in Europe.

The majority of trials focus on biological therapies, particularly monoclonal antibodies targeting specific inflammatory pathways. Several medications appear frequently across the trials, including vedolizumab, risankizumab, ustekinumab, adalimumab, and infliximab. Many studies are investigating new drugs such as guselkumab, ozanimod, tulisokibart, and various experimental compounds in early-phase trials.

Several trials are specifically designed for pediatric patients, recognising the importance of finding effective treatments for children with moderate to severe Crohn’s disease. Studies are also investigating optimal dosing strategies, including comparison of intravenous versus subcutaneous administration routes.

Innovative approaches being tested include fecal microbiota transplantation, stem cell therapies using adipose tissue-derived mesenchymal cells, and novel small molecule inhibitors. Some trials focus on specific complications of Crohn’s disease, such as intestinal strictures and perianal fistulas.

The trials employ various study designs, including placebo-controlled trials, active comparator trials, and long-term extension studies to evaluate safety and sustained efficacy. Many studies aim to achieve clinical remission without corticosteroids, which represents an important goal in Crohn’s disease management.

These ongoing clinical trials demonstrate the active research effort to develop more effective and better-tolerated treatments for patients with Crohn’s disease across all age groups.